Jupiter Neurosciences, Inc. has a market cap of $131.5 million. The company, founded in 2016, focuses on developing treatments for neuro-inflammation, particularly targeting diseases like Parkinson’s and Alzheimer’s.
Their main product, JOTROL, is a patented resveratrol solution designed to improve absorption in the body, delivered in a softgel capsule containing 100mg of resveratrol. Pre-clinical studies have shown that JOTROL has higher bioavailability compared to traditional resveratrol products.
Jupiter has completed a Phase I clinical trial that met its goals, paving the way for Phase II trials in Parkinson’s Disease. They aim to begin these trials using funds from their IPO.
The company has received interest from Asian organizations due to the growing use of resveratrol in traditional medicine and recent patent approvals in Hong Kong and China. They have also established service agreements to enter the Southeast Asian market.
The CEO, Christer Rosén, presented the company’s progress at BIOHK 2023. Jupiter Neurosciences plans to focus on expanding its clinical trials and developing treatments for rare diseases, particularly targeting conditions like Mucopolysaccharidoses Type 1 and MELAS.
For more information, Jupiter Neurosciences is located at 1001 North US HWY 1, Suite 504, Jupiter, Florida 33477, and can be contacted at (561) 406-6154 or via their website at jupiterneurosciences.com.
Receive Daily Updates: Enter your email to get news and ratings for Jupiter Neurosciences and other companies through MarketBeat.com’s FREE daily email newsletter.
`
